BioSpace News Archive

Immix Biopharma, Inc. today announced study data showing that ImmixBio’s lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer.

Suneva Medical, Inc. (“Suneva” or the “Company”), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, and Viveon Health Acquisition Corp. (NYSE American: VHAQ) (“Viveon Health” or “VHAQ”), a special purpose acquisition company, announced today that they have entered into a definitive merger agreement.

Mendix developed a flexible workflow driven digital questionnaire to document the side effects of coronavirus vaccinations for special groups and booster vaccinations.

Blade Therapeutics, Inc. today announced the successful completion of a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.

Avinger, Inc. today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale in a registered direct offering of an aggregate of 7,600 shares of Series D convertible preferred stock.

Abiomed (NASDAQ: ABMD) announces the successful results of the first-in-human early feasibility study of the preCARDIA system.

PsychoGenics Inc. announced that the National Institutes of Health (NIH) has completed the assessment of PsychoGenics data/IT security standards and systems, and gave official authority to operate as a government contractor.

Procaps Group, a leading integrated international healthcare and pharmaceutical company, announced the closing of an asset purchase agreement to acquire an 86,000 sq. ft.

Abbott (NYSE: ABT) today announced it has received clearance from the U.S. Food and Drug Administration for the EnSite™ X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S. and across Europe that is designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias.

THREAD, a leading technology and service provider enabling electronic clinical outcome assessments (eCOA) and decentralized clinical trials (DCTs), today announced that it has acquired inVibe, the leading voice-powered research and insights technology solution for the life sciences and health care industry.